Acino Holding AG : Avista Capital Partners and Nordic Capital hold 93.58% of Acino's share capital

NEWS RELEASE - PRESSEMITTEILUNG

Avista Capital Partners and Nordic Capital hold 93.58% of Acino's share capital

Aesch, December 6, 2013, 07.00 hrs - On October 4, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, published a public tender offer for all publicly held registered shares of Acino Holding AG for an offer price of CHF 115 per share in cash.

Provisional final result

Until the expiration of the additional acceptance period on December 5, 2013, 16.00 hrs,

3 237 774 Acino shares have been tendered under the tender offer. It results a participation of 93.58% of the share capital and the voting rights of Acino.

Definitive announcement of the final result

The present final result is preliminary. The definitive announcement of the final result will be published on December 11, 2013 in the Neue Zürcher Zeitung and in Le Temps.

Settlement

It is intended to pay the offer price (CHF 115 per Acino share less the gross amount of any dilution effects) for the Acino shares validly tendered during the offer period and the additional acceptance period on December 12, 2013.

Sales restrictions

The tender offer is subject to the sales restrictions according to the Offer Prospectus. The

Offer Prospectus and all other tender offer documents are accessible under www.pharmastrategypartners.com.

Definition of Nordic Capital

In this press release, when referring directly or indirectly to the tender offer, or the ownership of Pharma Strategy Partners GmbH, "Nordic Capital" is defined as "one of

Nordic Capital Fund VII and Nordic Capital Fund VIII". In any other context or description in this press release, "Nordic Capital" refers to "Nordic Capital Funds VII and VIII, and/or all,

or some, of their predecessor funds".

Advisors

Lazard is acting as lead financial advisor and Credit Suisse as financial advisor in the context of the public tender offer to Avista and Nordic Capital.

Acino Holding AG

Dornacherstrasse 114

CH-4147 Aesch

Phone [phone]

Fax [phone] www.acino-pharma.com

Contacts

For Acino:

Weber-Thedy Corporate & Financial Communications

Eva Kalias

[phone] [e-mail]

For Pharma Strategy Partners GmbH, Avista and Nordic Capital: Lemongrass Communications

Andreas Hildenbrand

[phone]

[e-mail]

About Acino

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 788 employees and generated revenues of EUR 143 million in the first half-year 2013.

About Avista Capital Partners

Avista Capital Partners is a leading private equity firm with over USD 5 billion under management. Founded in 2005, Avista's strategy is to make controlling or influential minority investments in growth- oriented energy, healthcare, communications & media, industrials, and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information consult www.avistacap.com.

About Nordic Capital

Nordic Capital invests in medium and large companies, primarily in the Nordic region and Germany, and in healthcare companies globally. Since 1989, Nordic Capital has supported value creation in its investments through committed ownership and by targeting strategic development and operational improvements, making Nordic Capital a leading presence in Northern European private equity. Committed capital is provided by international institutional investors, such as pension funds, asset managers and insurance companies. The Nordic Capital Funds are based in Jersey, Channel Islands and are advised by the NC Advisory companies in Sweden, Denmark, Finland, Norway, Germany
and the UK. Additional information is available at www.nordiccapital.com.

Acino Holding AG

Page 2 / 3

Dornacherstrasse 114

CH-4147 Aesch

Telefon [phone]

Fax [phone] www.acino-pharma.com

Disclaimers

The public tender offer (öffentliches Kaufangebot) (the «Tender Offer» or «Offer») described in this media release will not be made, directly or indirectly, in any country or jurisdiction, in which the Offer would be illegal or would otherwise violate any applicable law or ordinance, or which would require Pharma Strategy Partners GmbH («Pharma Strategy Partners» or the «Offeror») to change the terms or conditions of the Offer in any way, to submit any additional filing to, or to perform any additional action in relation to, any governmental, regulatory or legal authority. It is not intended to extend the Offer to any such country or jurisdiction. Documents relating to the Offer must not be distributed in or sent to any such countries or jurisdictions. Any such documents must not be used for the purpose of soliciting the sale or purchase of securities of Acino by any person or entity resident or incorporated in any such country or jurisdiction.

United States of America

The public tender offer described in this media release will not be made directly or indirectly in or by use of the mail of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States of America and may only be accepted outside the United States of America. This includes, but is not limited to, facsimile transmission, telex or telephones. This media release and any other offering materials with respect to the public tender offer described in this media release may not be distributed in nor sent to the United States of America and may not be used for the purpose of soliciting the sale or purchase of any securities of Acino, from anyone in the United States of America. The Offeror is not soliciting the tender of securities of Acino by any holder of such securities in the United States of America. Securities of Acino will not be accepted from holders of such securities in the United States of America. Any purported acceptance of the offer that the Offeror or its agents believe has been made in or from the United States of America will be invalidated. The Offeror reserves the absolute right to reject any and all acceptances determined by them not to be in the proper form or the acceptance of which may be unlawful.

United Kingdom

This communication is directed only at persons in the U.K. who (i) have professional experience in matters relating to investments, (ii) are persons falling within article 49(2)(a) to (d) («high net worth companies, unincorporated associations, etc.») of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as «relevant persons»). This communication must not be
acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons.

Australia, Canada and Japan

The public tender offer is not addressed to shareholders of Acino whose place of residence, seat or habitual abode is in Australia, Canada or Japan, and such shareholders may not accept the offer.

Cautionary statement regarding forward looking statements

This media release contains forward looking statements. Such statements may be identified by words such as "expects", "intends", "plans", "believes", "will" or words of similar meaning. Forward looking statements are based on the current expectations and assumptions of Acino and are therefore
subject to risks and uncertainties, many of which are beyond Acino's control. Due to these risks and uncertainties the actual results could differ materially from Acino's expectations expressed herein. Acino assumes no duty to update the information contained in this media release to reflect
subsequent developments.

Acino Holding AG

Page 3 / 3

Dornacherstrasse 114

CH-4147 Aesch

Telefon [phone]

Fax [phone] www.acino-pharma.com